Bayesian Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Bayesian Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-38,600	Closed	-$4.85M	–	713
2025 Q2	$4.85M	Buy	+38,600	New	+$4.43M	0.77%	18
2024 Q2	–	Sell	-12,453	Closed	-$1.72M	–	970
2024 Q1	$1.72M	Buy	12,453 +3,800	+44%	+$519K	0.16%	180
2023 Q4	$1.14M	Buy	+8,653	New	+$996K	0.12%	208
2023 Q1	–	Sell	-3,500	Closed	-$418K	–	989
2022 Q4	$418K	Buy	+3,500	New	+$410K	0.06%	400
2022 Q2	–	Sell	-8,713	Closed	-$817K	–	976
2022 Q1	$817K	Buy	+8,713	New	+$738K	0.12%	252
2020 Q4	–	Sell	-4,600	Closed	-$442K	–	600
2020 Q3	$442K	Buy	+4,600	New	+$532K	0.11%	254
2020 Q1	–	Sell	-14,184	Closed	-$1.52M	–	912
2019 Q4	$1.52M	Buy	+14,184	New	+$1.49M	0.26%	95
2018 Q4	–	Sell	-3,109	Closed	-$382K	–	724
2018 Q3	$382K	Buy	+3,109	New	+$353K	0.06%	389
2018 Q1	–	Sell	-11,340	Closed	-$880K	–	744
2017 Q4	$880K	Buy	11,340 +6,874	+154%	+$469K	0.18%	193
2017 Q3	$274K	Buy	+4,466	New	+$236K	0.07%	385

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bayesian Capital Management's NBIX Position: Q3 2025 in Review

Bayesian Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 38,600 shares — an estimated $4.85M sold.

Bayesian Capital Management first reported a position in NBIX in Q3 2017 and held it in 10 quarters. The position peaked at $4.85M in Q2 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

Bayesian Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
Bayesian Capital Management sold 38,600 Neurocrine Biosciences shares in Q3 2025, an estimated $4.85M.
Bayesian Capital Management first reported a position in Neurocrine Biosciences in Q3 2017 and held it in 10 quarters.
Bayesian Capital Management's Neurocrine Biosciences position peaked at $4.85M in Q2 2025.
649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.